Article thumbnail

Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study

By Enas A Hamed and Nagla T ElMelegy
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2894023
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1985). A short guide to the management of thalassemia. Thalassemia Today. 2nd Mediteranean Meeting on Thalassemia: Centro Transfusionale Ospetale Maggiore Polyclinico di
  2. (2003). A: Benefits and risks of deferiprone in iron overload in thalassemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf
  3. (2007). A: Cystatin C and beta-2-microglobulin: markers of glomerular filtration in critically ill children. Crit Care
  4. (2005). A: Cystatin C as a marker of GFR history, indications, and future research. Clin Biochem
  5. (2008). A: Renal function in children with β-thalassemia major and thalassemia intermedia. Pediatr Nephrol
  6. (1993). A: Replacement of metmyoglobin as a peroxidase source by horse radish peroxidase. Clin Sci
  7. (1998). A: Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephrol
  8. (1987). A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am
  9. (1986). AM: Use of beta-2-microglobulin to diagnose tubulo-interstitial renal lesions in children. Kidney Int
  10. (2008). Arzanian MT: Early markers of renal dysfunction in patients with beta thalassemia major. Pediatr Nephrol
  11. (2000). Athanasio M: Urine biochemical markers of early renal dysfunction are associated with iron overload in b-thalassaemia. Clin Lab Haem
  12. (2010). Athanassiou-Metaxa M: Renal Dysfunction in Patients with BetaThalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox. Acta Haematol
  13. (1978). Aust SD: Microsomal lipid peroxidation modified by adding the BHT solution to prevent further lipid peroxidation during boiling. Methods Enzymology
  14. (1985). Barakat AY: Thalassemia B with distal renal tubular acidosis: a previously undescribed association.
  15. (1999). Cao G: In vivo total antioxidant capacity: comparison of different analytical methods. Free Radic Biol Med
  16. (2000). Dikmen N: Renal function in pediatric patients with β-thalassemia major. Pediatr Nephrol
  17. (1976). Dosiadis S: Phosphaturia in thalassemia. Pediatrics
  18. (2006). Early blood transfusions protect against microalbuminuria in children with sickle cell disease. Pediatr Blood Cancer
  19. (2008). EF: Comparative study of cystatin C and serum creatinine in the estimative of glomerular filtration rate in children. Clinica Chimica Acta
  20. (2003). Frei sleben HJ: Iron status and oxidative stress in beta-thalassaemia patients in Jakarta. Biofactors
  21. (1975). Function of the kidney in adult patients with Cooley's disease. A preliminary report. Nephron
  22. (2007). H: A new approach for evaluating renal function and its practical application.
  23. (2003). Hoppe B: Urinary NAG in children with urolithiasis, nephrocalcinosis, or risk of urolithiasis. Pediatr Nephrol
  24. (1997). Iron overload and urinary lysosomal enzyme levels in beta-thalassemia major.
  25. (1994). JP: Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. Arch Dis Child
  26. (2006). Lemmey A: GFR estimation using cystatin C is not independent of body composition.
  27. (2005). Levey AS: Measurement of kidney function.
  28. (1992). Markers for the diagnosis and monitoring of renal tubular lesions. Clin Nephrol Suppl
  29. (1991). NF: The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
  30. (1998). Nilwarangkur S: Renal function in adult beta thalassemia/Hb E disease. Nephron
  31. (2006). Papassotiriou I: Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. Kidney Int
  32. (1976). Rapid colorimetric assay of β-galactosidase and N-acetyl-β-D-glucosaminidase in human urine. Clinica Chimica Acta
  33. (1994). S: Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Kidney Int
  34. (1990). Schiliro G: Acute changes in renal function associated with deferoxamine therapy.
  35. (2002). Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis.
  36. (1997). Siamopoulos KC: Renal abnormalities in patients with sickle cellbeta thalassemia.
  37. (2001). Siest G: Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med
  38. (1985). Skaarup P: β2-Microglobulin in urine and serum determined by ELISA technique.
  39. (2000). Survival in beta-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet
  40. (2003). Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Hematol
  41. (2003). Vongjirad A: Renal tubular dysfunction in alpha thalassemia. Pediatr Nephrol
  42. (1998). Vongjirad A: Renal tubular function in beta-thalassemia. Pediatr Nephrol